Journal of Clinical Oncology
Articles in this Issue
Updated overall survival, safety, and neurologic function outcomes from a phase 1 trial of bivalent chimeric antigen receptor (CAR) T cell therapy in recurrent glioblastoma (GBM).
2013 Background: We previously reported the safety, bioactivity, and preliminary efficacy of bivalent CAR T cells targetin...
Efficacy and safety results of tazemetostat in Japanese patients with advanced epithelioid sarcoma: The phase 2 TAZETTA trial (NCCH2107).
11560 Background: Epithelioid sarcoma is an ultra-rare soft tissue sarcoma with limited treatment options. Tazemetostat, a...
Incidence, prevalence, and temporal trends of colorectal cancer across age, sex, race, and ethnicity: A large real-world analysis.
e15699 Background: Colorectal cancer (CRC) remains a leading cause of cancer-related morbidity and mortality in the United...
Analytical characterization of the next-generation HER2 (CAL27) immunohistochemistry assay: A comparative multi-tumor study.
e15173 Background: HER2 protein expression has been observed in a variety of solid tumors. Advancements in antibody drug c...
Global trends in early-onset uterine cancer and the rising BMI-attributable burden: A population-based analysis, 1990–2023.
e17644 Background: Uterine cancer incidence has increased globally over recent decades, with growing concern regarding ris...
<i>EGFR</i> -mutated lung cancer: A comparative analysis of common and uncommon variants.
8635 Background: Uncommon EGFR mutations represent a heterogeneous subset of EGFR-positive NSCLC with limited characteriza...
A familiar paradox in a new exposure: Electronic cigarettes and thyroid cancer.
e22601 Background: Electronic cigarette (e-cigarette) use has increased rapidly in recent years, particularly among younge...
Supporting treatment resilience with optimized nutrition and guided exercise (STRONGER) in head and neck cancer patients undergoing chemoradiation.
TPS12161 Background: Patients with head and neck cancer (HNC) undergoing concurrent chemoradiation (chemoRT) frequently ex...
Pilot trial of virtual and in-person symptom screening with targeted early palliative care (STEP2).
12074 Background: Routine early palliative care (EPC) for patients with advanced cancer improves quality of life. To incre...
Early vs delayed bone-modifying agent initiation and zoledronic acid vs denosumab in newly diagnosed multiple myeloma.
e19573 Background: Bone-modifying agents (BMAs) reduce skeletal-related events (SREs) in multiple myeloma, but real-world...
Impact of sustained MRD negativity for up to 5 years on long-term outcome of transplant-eligible newly diagnosed multiple myeloma patients enrolled in the randomized phase 2 FORTE trial.
7504 Background: Novel combinations induce high rates of minimal residual disease (MRD) negativity (neg) in multiple myelo...
Comparative inpatient outcomes among FDA-approved chimeric antigen receptor T-cell products: An analysis of the 2023 National Inpatient Sample.
e23088 Background: Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the treatment landscape for relapsed o...
Trends in mortality due to lung cancer in patients with respiratory tract infections in the United States, 1999–2023: A CDC population-based analysis.
e20061 Background: Lung cancer remains the leading cause of cancer-related mortality in the United States. Respiratory tra...
Immune checkpoint inhibitors and respiratory outcomes in cancer patients with pre-existing asthma: A TriNetX propensity-matched cohort study.
11150 Background: Immune checkpoint inhibitors (ICIs) are associated with immune-related pulmonary toxicity. Real-world da...
Association of prophylactic G-CSF use with survival outcomes in patients with aggressive B-cell lymphomas treated with R-CHOP.
e19061 Background: R-CHOP is the standard first-line regimen for aggressive CD20-positive B-cell lymphomas, including diff...
Izalontamab brengitecan (iza-bren) versus chemotherapy in patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC): A multicenter, randomized, open-label, phase III study.
4008 Background: Chemotherapy plus a PD-1/PD-L1 inhibitor is the standard first-line treatment for PD-L1 expressing advanc...
Mutation landscape and pathway-level disparities in Black versus White patients with acute myeloid leukemia.
6534 Background: Racial disparities in acute myeloid leukemia (AML) outcomes are well-documented, yet race- specific genom...
Risk of venous thromboembolism in lung cancer patients treated with chemotherapy versus immunotherapy: A propensity-matched TriNetX analysis.
e20070 Background: Venous thromboembolism (VTE) is a major cause of morbidity and mortality in patients with lung cancer....
Real-world outcomes of amivantamab monotherapy in advanced EGFR-mutant non-small cell lung cancer.
e20717 Background: Amivantamab, a bispecific EGFR/MET antibody, is approved for EGFR exon 20 insertion-mutant non-small ce...
Endothelin-1 levels in lung tissue of patients with non–small cell lung cancer with previous COVID-19 of varying severity.
e20045 Background: COVID-19 is a multisystem disease, largely due to vascular endothelial damage, and poses a risk to pati...
Efficacy and safety of efbemalenograstim alfa versus PEG-rhG-CSF in preventing neutropenia in patients with locally advanced nasopharyngeal carcinoma undergoing induction chemotherapy followed by concurrent chemoradiotherapy.
e18064 Background: Preventing chemotherapy-induced neutropenia (CIN) is critical in locally advanced nasopharyngeal carcin...
<i>EGFR</i> mutational landscape in non–small cell lung cancer: A 10-year experience of a national reference laboratory in Colombia (2014–2023).
e20565 Background: Non-small cell lung cancer (NSCLC) accounts for approximately 80% of lung cancer cases globally. Target...
A quiet crisis: Pancreatic cancer incidence, mortality, and DALYs in Latin America and the Caribbean (1980-2023).
e16395 Background: Pancreatic cancer remains a leading cause of cancer mortality globally, largely because it is frequentl...
Emergency department visits and hospitalizations in cancer survivors with disabilities: A national analysis.
1643 Background: One in four Americans has a disability. Adults with disabilities are known to have a higher cancer burden...
Impact of protein–energy malnutrition on outcomes of metastatic triple-negative breast cancer patients receiving chemotherapy: A real-world analysis.
1135 Background: Protein–energy malnutrition (PEM) is common in patients with advanced cancer and is associated with incre...